This information is provided for guidance only and has been developed on the basis of current knowledge of the subject matter. It should not be relied upon to address every aspect of the relevant legislation.
If you have further questions, or you require further clarification of a particular requirement, you can email your questions to the Manufacturing Quality Branch.
Medicinal cannabis products
In 2016 the Australian Government amended the Narcotic Drugs Act 1967 to allow the cultivation and production of cannabis for medicinal purposes.
The Narcotic Drugs Act 1967 gives effect to the United Nations Single Convention on Narcotic Drugs 1961 (the Single Convention) requirements on cultivation, production of cannabis and the manufacture of narcotic drugs. Existing supply pathways (such as those under the Therapeutic Goods Act 1989) apply to all medicinal cannabis products cultivated or manufactured under the Narcotic Drugs Act 1967.
The Narcotic Drugs Act 1967 defines 'medicinal cannabis product' to mean a product, including but not limited to, a substance, composition, preparation or mixture, that:
includes, or is from, any part of the cannabis plant; and
is for use for the purposes of curing, or alleviating the symptoms of, a disease, ailment or injury
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.